Legal update regarding Risdiplam - Commercial Appellate Division of the Hon'ble Delhi High Court Dismissed Appeal

NATCO Pharma Limited (BSE: 524816 and NSE: NATCOPHARM) ("NATCO") today updates on the legal proceedings on Risdiplam launch in India.

With reference to earlier update on 8th April 2025, the Ld. Single Judge of Delhi High Court had through order dated 24.03.2025 denied Roche's plea for an injunction against the Company for the drug. Roche's appeal before the appellate Bench Delhi Court was announced today dated 9th October 2025 as appeal refused and consequently the status quo has been removed.

Today, in a landmark decision, the Commercial Appellate Division of the Hon'ble Delhi High Court, dismissed an appeal filed by the Swiss Pharmaceutical Company F. Hoffmann-La Roche AG.

With arguments spanning over several months, a Ld. Single Judge of the Hon'ble Delhi High Court, in groundbreaking judgment dated 24.03.2025, paved the way for NATCO to launch a generic version of the drug 'Risdiplam' which is used for treatment of the debilitating disease Spinal Muscular Atrophy (SMA). SMA is one of the leading causes of death in infants related to the degeneration of neurons. Currently, there are no curative treatment options for SMA, and most of the available options are not financially feasible for Indian patients. The Ld. Single Judge had factored the challenge of invalidity of Roche's patent and laid special emphasis on the public interest, considering the Swiss Company's pricing had rendered the drug inaccessible and unaffordable to the bulk of its patients.

The Appeal was preferred against the said order of the Ld. Single Judge. In a first of its kind, in dismissing the appeal, the Division Bench has removed the final hurdle in allowing a lifesaving drug like Risdiplam to be accessible at an affordable price to the Indian patients. This ruling would bring some hope to the countless lives that have been debilitated by an ailment like Spinal Muscular Atrophy (SMA).

The Company has decided to launch the product with immediate effect and price the product at INR 15,900 MRP consistent with the Company's stand before the court. The Company also intends to offer some discount to certain deserving patients through its patient access programme.

Shares of Natco Pharma Limited was last trading in BSE at Rs. 813.55 as compared to the previous close of Rs. 808.25. The total number of shares traded during the day was 11462 in over 882 trades.

The stock hit an intraday high of Rs. 821.30 and intraday low of 810.65. The net turnover during the day was Rs. 9335561.00.

Source : Equity Bulls

Keywords

NatcoPharma INE987B01026 Pharmaceuticals Risdiplam LegalUpdate